Table 1. Mutations identified in viral RNA amplified from serum of the persistently infected tamarin T12025 between weeks 40 and 48 of infection

Nucleotide Position	pGBV-B/2 AY243572	T12025 Virus	Location	AA Residue	pGBV-B/2	T12025 Virus
1612	A	G	E2	389	Pro	-
1849	C	T	E2	468	Gly	-
2783	**T**	**G**	**NS2**	**780**	**Phe**	**Glu**
3001	T	C	NS2	852	Val	-
3793	A	C	NS3	1116	Gly	-
4396	**C**	**A**	**NS3**	**1317**	**Asn**	**Lys**
4435	T	C	NS3	1330	Tyr	-
5090	**A**	**G**	**NS3**	**1549**	**Thr**	**Ala**
5212	T	G	NS4A	1589	Arg	-
5225	**G**	**A**	**NS4A**	**1594**	**Ala**	**Thr**
5305	C	T	NS4B	1620	Pro	-
6061	T	C	NS5A	1872	Ile	-
6993	**T**	**C**	**NS5A**	**2183**	**Met**	**Thr**
7031	**T**	**C**	**NS5A**	**2196**	**Phe**	**Leu**
7152	**T**	**C**	**NS5A**	**2236**	**Val**	**Ala**
7248	**G**	**A**	**NS5A**	**2268**	**Gly**	**Glu**
7303	C	T	NS5B	2286	Phe	-
7357	C	T	NS5B	2304	Leu	-
7711	C	T	NS5B	2422	Thr	-
8402	**T**	**C**	**NS5B**	**2653**	**Tyr**	**His**
8942	**A**	**G**	**NS5B**	**2833**	**Ile**	**Val**
8969	**T**	**G**	**NS5B**	**2842**	**Phe**	**Val**
9299	G	A	3'NTR*	NA	NA	NA

Nonsilent mutations are bold. –, amino acids identical to parental GBV-B/2 residues. Mutations at nucleotides 5090, 6061, and 8942 were present at week 40 or 42, but partly or completely reverted to the pGBV-B/2 sequence at week 44 or 48. NA, not applicable. The two nonsilent mutations (Ala-1594 → Thr and Val-2236 → Ala in NS4A and NS5A, respectively) eliminate two of the three amino acid differences that distinguish the pGBV-B/2

sequence from that of the infectious molecular clone (GenBank accession no. AF179612) reported by Bukh *et al.* (1).

*3' NTR, 3' nontranslated RNA.

1. Bukh, J., Apgar, C. L. & Yanagi, M. (1999) *Virology* **262,** 470–478.